JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

Inicio・Lista de Acciones・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Cerrado

SectorSanidad

7.35 0.68

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

7.16

Máximo

7.38

Métricas clave
By Trading Economics
Ingresos	5.7M -30M
Ventas	3.1M 34M
Margen de beneficios	-89.424
Empleados	182
EBITDA	5.2M -35M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+230.58% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	76M 759M
Apertura anterior	6.67
Cierre anterior	7.35

Noticias sobre sentimiento de mercado

By Acuity

50%

163 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

6.26 / 7.47 Soporte y Resistencia

Day One Biopharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 oct 2025, 20:49 UTC

Ganancias

Correction to Thermo Fisher Article on Oct. 22

23 oct 2025, 23:51 UTC

Charlas de Mercado

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 oct 2025, 23:49 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 oct 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 oct 2025, 23:37 UTC

Charlas de Mercado

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 oct 2025, 22:58 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

23 oct 2025, 22:57 UTC

Charlas de Mercado

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 oct 2025, 22:49 UTC

Adquisiciones, fusiones, absorciones

How Trump Sparked a New Era of State Capitalism -2-

23 oct 2025, 22:49 UTC

Adquisiciones, fusiones, absorciones

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 oct 2025, 22:17 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 oct 2025, 21:41 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 oct 2025, 21:05 UTC

Ganancias

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 oct 2025, 20:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

23 oct 2025, 20:50 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

23 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

23 oct 2025, 20:35 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 oct 2025, 20:28 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 oct 2025, 20:15 UTC

Charlas de Mercado

Ganancias

Global Commodities Roundup: Market Talk

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q Adj EPS $1.71

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q Sales $5.52B

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q EPS $1.67

23 oct 2025, 20:09 UTC

Ganancias

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 oct 2025, 20:07 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

23 oct 2025, 20:07 UTC

Charlas de Mercado

Ganancias

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 oct 2025, 20:07 UTC

Ganancias

Blackstone Looks to IPOs for Investment Exits -- Update

23 oct 2025, 20:05 UTC

Ganancias

Intel 3Q Gross Margin 38.2% >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 oct 2025, 20:04 UTC

Ganancias

Intel: 4Q Guidance Excludes Altera >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel Sees 4Q Adj EPS 8c >INTC

Comparación entre iguales

Cambio de precio

Day One Biopharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

230.58% repunte

Estimación a 12 Meses

Media 24 USD 230.58%

Máximo 34 USD

Mínimo 16 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Day One Biopharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para Day One Biopharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

6.26 / 7.47Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentimiento

By Acuity

163 / 371 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.